PLATIPUS is an adaptive platform trial aimed at improving the health of infants born preterm (before 37 weeks' gestation). PLATIPUS will compare how different treatments and care provided to pregnant women and people at risk of preterm birth and infants born preterm affect infant health.
The main questions PLATIPUS aims to answer are:
1. What effect/s do different treatments/care provided to pregnant women and people at risk of preterm birth have on the health of their infants? (Pregnancy domains)
2. What effect/s do different treatments/care given to infants born preterm have on their health ? (Neonatal domains).
This registration record relates to the PLATIPUS Core (or 'master') protocol which provides guidance for the overall running of the trial. Additional appendices will outline the aims, questions, treatments, and activities for each separate research question (domain). Each Domain-Specific Appendix will be registered separately on ClinicalTrials.gov and will link to this record.

开始日期2025-02-01

申办/合作机构

University of Melbourne

[+10]

ACTRN12624001295538 / Not yet recruitingN/AIIT

Is rectus abdominis training, or transversus abdominis training, or natural recovery, more effective for reducing the inter-recti distance in women with Diastasis of the Rectus Abdominis Muscles during the early postpartum period? A randomized controlled trial.

开始日期2024-11-25

申办/合作机构

LaTrobe University

ACTRN12624000536561 / RecruitingN/AIIT

Telehealth delivered motivational interviewing and cognitive behaviour therapy to support exercise-based rehabilitation for people with lower limb osteoarthritis: a pilot randomized control trial

开始日期2024-07-15

申办/合作机构

LaTrobe University

100 项与 LaTrobe University 相关的临床结果

登录后查看更多信息

0 项与 LaTrobe University 相关的专利（医药）

登录后查看更多信息

23,173

项与 LaTrobe University 相关的文献（医药）

2025-09-20·Annual Review of Physiology

From Muscle-Based Nonshivering Thermogenesis to Malignant Hyperthermia in Mammals

Review

作者: Launikonis, Bradley S. ; Murphy, Robyn M.

For physiological processes in the vital organs of eutherian mammals to function, it is important to maintain constant core body temperature at ∼37°C. Mammals generate heat internally by thermogenesis. The focus of this review is on heat generated in resting skeletal muscles, using the same cellular components that muscles use to regulate cytoplasmic calcium concentrations [Ca2+] and contraction. Key to this process, known as muscle-based nonshivering thermogenesis (MB-NST), are tiny Ca2+ movements and associated ATP turnover coordinated by the plasma membrane, sarcoplasmic reticulum (SR), and the mitochondria. MB-NST has made mammals with gain-of-function SR ryanodine receptor (RyR) variants vulnerable to excessive heat generation that can be potentially lethal, known as malignant hyperthermia. Studies of RyR variants using recently developed techniques have advanced our understanding of MB-NST.

2025-02-01·Intensive and Critical Care Nursing

Moving on from a “good death”: Child- and family-centred end-of-life care in paediatric critical care

Article

作者: Butler, Ashleigh E. ; Bloomer, Melissa J ; Butler, Ashleigh E ; Bloomer, Melissa J.

2025-01-29·International journal of nursing education scholarship

Gerontological educational interventions for student nurses: a systematic review of qualitative findings

Review

作者: Dahlke, Sherry ; Kennedy, Megan ; Butler, Jeffrey I ; Rayner, Jo-Anne ; Fetherstonhaugh, Deirdre

Abstract:

Objectives:

This systematic review of qualitative studies explored interventions to improve student nurses’ knowledge, attitudes or willingness to work with older people. Student nurses are likely to encounter older people in all health and aged care settings, however, research demonstrates that few have career aspirations in gerontological nursing.

Methods:

Qualitative systematic review method based on the Cochrane Handbook for Systematic Reviews of Interventions.

Results:

Search of Medline, Embase, PsycINFO, EBSCOhost and Scopus yielded 1841 articles which were screened to include primary research about educational interventions to improve student nurses’ knowledge, attitudes and/or willingness to work with older people. Data extraction was performed on the 14 included studies, and data were analysed using directed content analysis. The Mixed Methods Appraisal Tool (MMAT) was used the assess the quality of the studies.

Conclusions:

Educational interventions included theory or practice courses, or a combination of theory and practice. While most interventions changed nursing students’ negative attitudes towards older people, few increased their willingness to work with them. Practice courses had the most significant impact on willingness to work with older people. Quality assessment revealed methodical limitations. More research is needed to better understand the elements of practice interventions that enhance student nurses’ knowledge, attitudes, and willingness to work with older people, so that they can be replicated.

项与 LaTrobe University 相关的新闻（医药）

2023-12-08

·FiercePharma

BioNTech lays out plan to build clinical-stage manufacturing site in Australia

BioNTech will break ground on a clinical-stage manufacturing site in Melbourne, Australia, next year. The move part of the drugmaker's effort to build bridges around the world, furthering its ambitions in creating innovative mRNA products. BioNTech has firmed up its plans in Australia, signing a multi-year partnership with the state of Victoria to research, develop and manufacture new mRNA medicines, with the goal of treating up to 4,000 cancer patients—in clinical trials or with authorized therapies—over a ten-year period in the region. BioNTech will build its research and clinical-stage manufacturing site at LaTrobe University’s Melbourne campus, breaking ground next year. At the site, the drugmaker will employ its mobile, digitally enabled modular manufacturing units, BioNTainers. One will manufacture mRNA and formulated drugs. A second unit will handle fill-finish, the company said. During a press event Friday morning at the planned site, government officials also announced that Victoria will build the Centre for AI in Medical Innovation (CAMI) next door to BioNTech’s site, which will develop artificial intelligence innovations and provide pathway opportunities for researchers and students. The agreement builds on a letter of intent the company signed with Victoria in October of 2022. “This partnership means more mRNA expertise in our state, more treatments for people with hard-to-treat cancers and 1,200 local jobs,” Victorian premier Jacinta Allan said at the press event, which included BioNTech’s chief operating officer Sierk Poetting. BioNTech also will set up an mRNA innovation center in Melbourne. The company added that it will identify mRNA-focused research projects from academia and the biotech industry and help transition them into clinical-stage development. With the success of its Pfizer-partnered COVID-19 vaccine Comirnaty, BioNTech has taken its growth ambitions worldwide. Last year, the company broke ground on a site in Kigali, Rwanda, which is due to come online next year. BioNTech also plans BioNTainer setups in South Africa and Senegal. “BioNTech’s vision is to translate science into survival,” CEO Ugur Sahin, M.D., said in a release. “The State of Victoria is one of the leading life sciences hubs in the Asia Pacific region, and we are looking forward to strengthening its cutting-edge research and development.”

疫苗信使RNA

2023-07-26

·生物谷

Nature：新研究首次揭示为何一些感染新冠病毒的人从未出现症状

感染 SARS-CoV-2冠状病毒但从未出现症状的人---所谓的超级躲避者（super dodger）---可能有遗传王牌。在一项新的研究中，来自美国加州大学旧金山分校等研究机构的研究人员发现这些超级感染 SARS-CoV-2冠状病毒但从未出现症状的人---所谓的超级躲避者（super dodger）---可能有遗传王牌。在一项新的研究中，来自美国加州大学旧金山分校等研究机构的研究人员发现这些超级躲避者携带特定基因变异的几率是那些出现症状的人的两倍多，而且这种基因变异可以帮助前者消灭这种病毒。相关研究结果于2023年7月19日在线发表在Nature期刊上，论文标题为“A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection”。这篇论文首次证明了无症状 SARS-CoV-2感染的遗传基础。这项研究有助于解开为什么有些人会感染SARS-CoV-2而不发病的谜团。其中的秘密在于人类白细胞抗原（HLA），即向免疫系统发出信号的蛋白标志物。编码 HLA 的一个基因发生了突变，这似乎有助于杀死病毒的 T 细胞识别 SARS-CoV-2 并发动闪电攻击。一些携带这种基因突变的人的 T 细胞可以识别SARS-CoV-2，即使他们以前从未接触过这种病毒，这要归功于它与他们已经了解的季节性感冒冠状病毒的相似性。这一发现为药物和疫苗提供了新的靶标。论文通讯作者、加州大学旧金山分校威尔神经科学研究所成员Jill Hollenbach博士解释说，“如果你有一支能够及早识别敌人的军队，那将是一个巨大的优势。这就好比有了做好战斗准备的士兵，他们已经知道要寻找什么，知道这些是坏人。” 这种突变---HLA-B*15:01---相当常见，研究人群中约有 10%携带这种突变。它并不能阻止SARS-CoV-2感染细胞，反而会阻止人们出现任何症状，包括流鼻涕，甚至是几乎不明显的喉咙痛。这些作者发现，在感染后仍无症状的研究人群中，有20%的人携带至少一个HLA-B*15:01变体拷贝，而在报告有症状的人群中，这一比例仅为9%。携带两个基因变体拷贝的人避免生病的几率要大得多，是报告有症状的人群的八倍多。利用美国国家骨髓捐献者数据库这些作者很早就猜测这与 HLA 有关，幸运的是，一个全国性的登记处包含了他们正在寻找的数据。美国国家骨髓捐献者计划/Be The Match 是美国最大的 HLA 类型志愿捐献者登记处，它为捐献者和需要骨髓移植的人牵线搭桥。但是他们仍需要了解捐献者对SARS-CoV-2的抵抗情况。于是，他们求助于加州大学旧金山分校开发的一款名为 COVID-19 公民科学研究（COVID-19 Citizen Science Study）的移动应用程序。他们招募了也在骨髓登记处进行了登记的近 3 万人，并在COVID-19大流行的第一年进行了跟踪。当时，疫苗尚未问世，许多人因工作需要或在可能暴露的情况下接受了常规 COVID -19检测。论文共同作者、加州大学旧金山分校流行病学与生物统计学教授Mark Pletcher博士说，“我们并没有打算研究遗传学，但我们很高兴看到我们与Hollenbach博士和美国国家骨髓捐献计划的多学科合作取得了这一成果。” 这个主要研究群体仅限于那些自我认同为白人的人，因为最终的研究受访者中没有足够的其他民族和种族群体的人可供分析。这些作者确定了 1428 名未接种疫苗的捐献者，他们在 2020 年 2 月至 2021 年 4 月底期间SARS-CoV-2检测结果呈阳性，当时疫苗还未广泛上市，而且检测结果还需要很多天才能出来。在这些人中，136 人在检测结果呈阳性前后至少两周内没有任何症状。只有一种HLA变异---HLA-B*15:01---与无症状SARS-CoV-2感染有很强的相关性，而且这种情况在两个独立的队列中都得到了证实。严重COVID-19感染的风险因素，如年龄较大、超重和患有糖尿病等慢性疾病，似乎与无症状感染无关。 NQK特异性T细胞具有交叉反应性。图片来自Nature, 2023, doi:10.1038/s41586-023-06331-x。论文共同作者、美国国家骨髓捐献计划/Be The Match 研究副主席Martin Maiers说，“我们很荣幸能合作开展研究，这类研究有可能利用长期公共投资来建立国家登记处，以帮助治愈疾病并提高我们避免未来流行病的能力。” 为了弄清 HLA-B15 是如何战胜这种病毒的，Hollenbach团队与澳大利亚拉筹伯大学的研究人员进行了合作。他们研究了T细胞记忆的概念，即免疫系统如何记住以前的感染。他们察了携带HLA-B15但从未接触过SARS-CoV-2病毒的人的T细胞，发现这些细胞仍然对这种病毒中名为NQK-Q8肽的一部分有反应。他们得出的结论是，暴露于一些季节性感冒冠状病毒（这些冠状病毒有一个非常相似的多肽，叫做NQK-A8），能使这些人体内的T细胞迅速识别SARS-CoV-2，并做出更快、更有效的免疫反应。拉筹伯大学教授兼实验室主任Stephanie Gras说，“通过研究他们的免疫反应，这也许能让我们找出促进对SARS-CoV-2免疫保护的新方法，从而可用于未来疫苗或药物的开发。”（生物谷 Bioon.com）参考资料： Danillo G. Augusto et al. A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection. Nature, 2023, doi:10.1038/s41586-023-06331-x.

疫苗临床结果紧急使用授权

2022-09-06

·生物谷

Nat Commun：一种天然机制或能让机体T细胞激活的敏感性增加50倍

来自拉筹伯大学等机构的科学家们通过研究发现了一种激活机体T细胞的新方法，其或能潜在增加基于T细胞的免疫疗法治疗的范围和成功率。 T细胞受体（TCR）和肽类-主要组织相容性复合体（pMHC）配体之间的相互作用通常是由非共价键所介导的。尽管免疫疗法在治疗一些癌症和自身免疫性疾病上已经取得了巨大的进步，但这类疗法对于很多患者而言似乎并不奏效。近日，一篇发表在国际杂志Nature Communications上题为“Covalent TCR-peptide-MHC interactions induce T cell activation and redirect T cell fate in the thymus”的研究报告中，来自拉筹伯大学等机构的科学家们通过研究发现了一种激活机体T细胞的新方法，其或能潜在增加基于T细胞的免疫疗法治疗的范围和成功率。这篇文章中，研究人员通过联合研究识别出了一种特殊机制，即T细胞如何对低剂量的抗原产生反应，他们发现了一种此前并未观察过的免疫相互作用，这种作用一直以来被认为是不可见的，因为T细胞的激活水平超过了通常会导致这些T细胞被从免疫系统中剔除的阈值。研究者发现了一种新型的生化机制，即T细胞在其完全成熟之前如何被剔除。一种天然机制或能让机体T细胞激活的敏感性增加50倍。图片来源：Nature Communications (2022). DOI: 10.1038/s41467-022-32692-4 研究者Szeto说道，我们进行了全面的基于生化的测定，并观察到了了抗原和T细胞抗原受体之间所形成的的共价键，我们利用X射线晶体学技术证实了二硫键的存在，他们提供的功能性证据表明，这种共价相互作用或许会导致T细胞激活的敏感性增加50倍，这一发现来自于科学家们对机体胸腺的基础研究，而胸腺是一种能促使机体免疫系统适合其宿主的器官。研究者表示，当我们开始这项研究时，免疫疗法并不在我们的考虑范围之内，但如今我们揭示了这种自然机制是如何在未来癌症和自身免疫性疾病疗法中被采用的。综上，本文研究结果表明，共价的T细胞受体-pMHC相互作用或许是一种生理性T细胞激活机制的潜在基础，其在基础便宜学和潜在的免疫疗法开发过程中都有一定的应用价值。（生物谷Bioon.com）原始出处： Christopher Szeto,Pirooz Zareie,Rushika C. Wirasinha, et al. Covalent TCR-peptide-MHC interactions induce T cell activation and redirect T cell fate in the thymus, Nature Communications (2022). DOI: 10.1038/s41467-022-32692-4

免疫疗法细胞疗法

100 项与 LaTrobe University 相关的药物交易

登录后查看更多信息

100 项与 LaTrobe University 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Travelan ( LPS )	自闭症更多	临床2期
IAP antagonists(La Trobe University) ( cIAP1 )	肿瘤更多	临床前
WO2022155705 ( TWEAKR )专利挖掘	肝病更多	药物发现
MSP2-C1 ( MSP-2 )	疟疾更多	无进展